Co-Diagnostics (NASDAQ: CODX)
Co-Diagnostics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Co-Diagnostics Company Info
Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.
News & Analysis
Why Co-Diagnostics Stock Slipped Today
Investors continued to avoid the company after its big second-quarter whiffs.
Why Shares of Co-Diagnostics Stock Fell 10% on Tuesday
The stock dropped two days before reporting second-quarter earnings.
Why Co-Diagnostics Stock Is Rising Today
It just got its new test for monkeypox out the door for the first time.
Why Co-Diagnostics Is Running Higher Today
Investors in the diagnostics and research outfit received a dose of beneficial news today.
Why Co-Diagnostics Trounced the Market on Thursday
The company is not monkeying around with the latest possible global health menace.
Why Co-Diagnostics Stock Tumbled by Nearly 12% Today
The company released its 2021 earnings, and investors weren't happy with them despite profitability guidance that beat estimates.
Why Co-Diagnostics Is Soaring Today
The diagnostics and research outfit gave investors a dose of good news today.
Why Co-Diagnostics, Ocugen, and Sorrento Stocks Are Sinking This Week
Even with COVID-19 cases rising, the prospects for these stocks remain uncertain.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.